Web Results

www.scotusblog.com/case-files/cases/glaxosmithkline-llc-v-m-m

Oct 2, 2017 ... May 30 2017, Brief of respondents M. M. ex rel, Meyers, et al. in opposition filed. ... Jun 15 2017, Reply of petitioner GlaxoSmithKline LLC filed.

www.phillipsandcohen.com/wp-content/uploads/Gerahty-et-al-v-GSK-complaint.pdf

V. UNITED STATES OF AMERICA. EX REL, THOMAS GERAHTY and ) C.A. No. ... SMITHKLINE BEECHAM CORP. d/b/a ) Govt Code $12650 et seq.

www.bna.com/glaxosmithkline-face-insurers-n57982082846

Nov 16, 2016 ... More than 40 insurance plans can proceed with claims GlaxoSmithKline misled them about the safety and effectiveness of drugs manufactured ...

news.findlaw.com/wsj/docs/glaxo/nyagglaxo60204cmp.pdf

wholly owned subsidiary of GlaxoSmithKline, pIc. (Defendant GlaxoSmithKline, pIc includes all of its predecessors and its past and cuuent components, ...

www.justice.gov/sites/default/files/opa/legacy/2012/07/02/us-complaint.pdf

Jul 2, 2012 ... GREG. THORPE, ET AL. (Consolidated]. Plaintiffs,. C.A. No. 11-10398-RWZ. V. FILED UNDER SEAL. GLAXOSMITHKLINE PLC, and.

www.researchgate.net/profile/Colin_Macphee

GlaxoSmithKline | GSK · Metabolic Pathways and Cardiovascular Division ... Alan H. Drummond ..... matrix metalloproteinase-9 mRNA expression was observed with darapladib 80 mg (P = 0.053 vs placebo). ...... coronary artery disease, and major adverse events at follow-up'† by E.S. Brilakis et al. , on page 137 Over the  ...